Effects of Electronic Cigarettes in Cigarette Smokers With Mild to Moderate COPD

NCT ID: NCT03379025

Last Updated: 2019-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-31

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effects of electronic cigarette use on cigarette smoking and markers of tobacco use, as well as respiratory symptoms and function in smokers with mild to moderate chronic obstructive pulmonary disease (COPD). All participants will receive a 12 week supply of electronic cigarettes to use instead of their regular conventional cigarettes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Electronic cigarettes are devices that heat a solution containing nicotine to form an aerosol that is then inhaled by the user. Electronic cigarettes are used by many smokers, including smokers with chronic health conditions such as COPD. Given that e-cigarettes are still relatively new, their effects on health are not well defined.

It is important to understand how electronic cigarettes affects symptoms and lung function in smokers with COPD to determine the short-term safety of these products. To do this, an initial step involves observing the extent to which smokers substitute their conventional cigarette use with electronic cigarette use and change their exposure to tobacco use biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Tobacco Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early Intervention Group

JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks

Group Type EXPERIMENTAL

Electronic cigarette

Intervention Type OTHER

electronic cigarette and cartridge refills (also known as pods)

Delayed Intervention Group

After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks

Group Type OTHER

Electronic cigarette

Intervention Type OTHER

electronic cigarette and cartridge refills (also known as pods)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electronic cigarette

electronic cigarette and cartridge refills (also known as pods)

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

e-cigarette, JUUL electronic cigarette

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 10 pack year smoking history
* Daily use of at least 5 cigarettes
* No plan to quit cigarettes in the next 30 days
* Willing to use e-cigarettes
* Diagnosis of COPD (FEV1/forced vital capacity \[FVC\] \<0.70) with mild (FEV1 \>80% predicted) or moderate (FEV1 \<80% but \>50% predicted) airflow limitation (post-bronchodilator); confirmed by spirometry
* English-speaking

Exclusion Criteria

* Past 30-day use of nicotine-containing products (cigars, cigarillos, hookah, electronic cigarettes, smokeless tobacco, nicotine replacement therapy)
* Past 30 day use of inhaled drugs (marijuana, crack)
* Pregnant or breastfeeding
* Planning to become pregnant within the next 3 months or unable to agree to use appropriate contraception during study
* Pulmonary disease other than COPD or asthma
* Ever requiring mechanical ventilation
* 2 or more hospitalizations for COPD in the past 12 months
* Cardiac hospitalization in the past 6 months
* Active chest pain or palpitations
* Uncontrolled hypertension (blood pressure \>160/100)
* Oxygen therapy
* Inability or contraindication to perform spirometry (e.g. recent eye, thoracic, or abdominal surgery)
* Known allergy to propylene glycol or vegetable glycerin
* Unable to consent or complete assessments
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massachusetts General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Kalkhoran

Assistant Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017P002418

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Healthy At Home Pilot
NCT06000696 COMPLETED
CAN BREATHE in COPD Trial
NCT03060993 UNKNOWN PHASE2